azn

It can sometimes be tough to get a straight answer about any potential problems with drugs from the companies that make them, if court records are any guide. AstraZeneca (AZN) told American doctors the company's antipsychotic drug Seroquel didn't cause diabetes, despite alerting Japanese physicians...

The pharmaceutical sector was on fire Monday, with successful trials, FDA approvals, and some deal action. So far, Tuesday is shaping up to be similar. Big pharma takes its hits for questionable practices. But on days like these, we remember the enormous value and contributions that drug companies...

AstraZeneca (AZN) has long hoped that its blood-thinner drug Brilinta was going to become a blockbuster. From the looks of things, the company may gets its wish. Back in May, the pharmaceutical company announced that its experimental heart drug Brilinta was more effective than Sanofi-Aventis...

Animal lovers range in intensity from those who wouldn't needlessly harm animals but definitely put human life ahead of animal life, to those who see them as equal, to those who put animal life ahead of human life. The public at large, I'd venture to guess, belongs to the first group for the most...

AstraZeneca (AZN) and Merck & Co (MRK) said that they will collaborate to research a novel combination anticancer regimen composed of two investigational compounds from Merck and AstraZeneca. According to preclinical trials (the laboratory phase), combining the two medicines could enhance their...

If you opened any financial newspaper or site today, you couldn't have missed it: AstraZeneca (AZN) announced that its experimental heart drug Brilinta was more effective than Sanofi-Aventis (SNY) and Bristol-Myers Squibb Co's (BMY) blockbuster Plavix in the prevention of cardiovascular events,...

The following post rounds up the companies making headlines today: Capital One Financial Corp. (COF), U.S. Bancorp (USB) and BB&T Corp. (BBT) are racing to repay government bailout funds after stress tests showed they wouldn't need additional capital to weather worsening economic conditions....

Investors have long heard of the problems plaguing Big Pharma, especially blockbuster drugs coming off patent in the near future, exposing them to competition from cheaper generics. A record number of drug sales will come off patent in the upcoming "patent cliff" arriving in 2010-2012. BusinessWeek...